Style | Citing Format |
---|---|
MLA | Mohtasham N, et al.. "Salivary Antiviral and Antibacterial Properties in the Encounter of Sars-Cov-2." Current Pharmaceutical Design, vol. 29, no. 27, 2023, pp. 2140-2148. |
APA | Mohtasham N, Bargi R, Farshbaf A, Shahri MV, Hesari KK, Mohajertehran F (2023). Salivary Antiviral and Antibacterial Properties in the Encounter of Sars-Cov-2. Current Pharmaceutical Design, 29(27), 2140-2148. |
Chicago | Mohtasham N, Bargi R, Farshbaf A, Shahri MV, Hesari KK, Mohajertehran F. "Salivary Antiviral and Antibacterial Properties in the Encounter of Sars-Cov-2." Current Pharmaceutical Design 29, no. 27 (2023): 2140-2148. |
Harvard | Mohtasham N et al. (2023) 'Salivary Antiviral and Antibacterial Properties in the Encounter of Sars-Cov-2', Current Pharmaceutical Design, 29(27), pp. 2140-2148. |
Vancouver | Mohtasham N, Bargi R, Farshbaf A, Shahri MV, Hesari KK, Mohajertehran F. Salivary Antiviral and Antibacterial Properties in the Encounter of Sars-Cov-2. Current Pharmaceutical Design. 2023;29(27):2140-2148. |
BibTex | @article{ author = {Mohtasham N and Bargi R and Farshbaf A and Shahri MV and Hesari KK and Mohajertehran F}, title = {Salivary Antiviral and Antibacterial Properties in the Encounter of Sars-Cov-2}, journal = {Current Pharmaceutical Design}, volume = {29}, number = {27}, pages = {2140-2148}, year = {2023} } |
RIS | TY - JOUR AU - Mohtasham N AU - Bargi R AU - Farshbaf A AU - Shahri MV AU - Hesari KK AU - Mohajertehran F TI - Salivary Antiviral and Antibacterial Properties in the Encounter of Sars-Cov-2 JO - Current Pharmaceutical Design VL - 29 IS - 27 SP - 2140 EP - 2148 PY - 2023 ER - |